Navigation Links
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Date:1/14/2008

ients maintain a higher ribavirin

dose. However, physicians could only prescribe EPO after the first dose

ribavirin reduction in the "IDEAL" trial. Since patients in the Peg-

Intron arms generally had smaller ribavirin dose reductions, this

introduces another potential bias and means those Peg-Intron patients

were potentially able to maintain a higher dose of ribavirin compared

to PEGASYS patients

About PEGASYS

PEGASYS was launched by Roche in 2002 and quickly became the leading treatment for patients with hepatitis C. It is indicated in combination with COPEGUS (ribavirin) for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA- approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treatment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and pa
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
11. Schering-Plough Reports Top-Line Results of the IDEAL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ...
(Date:1/14/2014)... Jan. 14, 2014   Oligomerix, Inc. , a privately held ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced today ... Valhalla, NY as of January 15, 2014 ... New York Medical College. Oligomerix, which is ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... March 16 Sigma-Aldrich® (Nasdaq: SIAL ) ... Ace Animals, Inc., a Berks County, PA. -based ... industry. Ace Animals ( www.aceanimals.com ), a commercial rodent ... contract breeding services, and will operate as part of ...
... , INDIANAPOLIS and MELBOURNE, Australia , ... (NYSE: LLY ) and Acrux (ASX: ACR) ... worldwide license agreement for the potential commercialization of Acrux,s ... drug application for AXIRON is currently under regulatory review ...
Cached Medicine Technology:Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 2Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 3Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 4Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 5Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 6Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 7Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 2Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 3Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 4Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 5
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective and ... patients. This is the result of a study led ... for Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. ... in advance of print in the American Journal ... C. diff , has increased to epidemic proportions ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... Montefiore Medical Center and the Albert ... present new findings at the Alzheimer,s Association International Conference ... Copenhagen, Denmark. Data from the four abstracts will focus ... to mild cognitive impairment and dementia. The research is ... in 1980 to examine healthy brain aging as well ...
(Date:7/9/2014)... and have a reputation for being highly toxic, but when ... being being found to offer potential health benefits in a ... dementia. A new compound (AP39), designed and made at the ... by targeting delivery of very small amounts of the substance ... Scientists in Exeter have already found that the compound protects ...
(Date:7/9/2014)... study conducted by researchers at Tufts University School of ... intellectual and developmental disabilities, the likelihood of having cavities ... increased. The findings, published in the July/August issue of ... interventions designed to address the oral health of individuals ... dental records of 107 patients at one of the ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... ... Areas, NEW YORK, March ... of Healthcare Providers and,Systems (HCAHPS) scores for hospitals nationwide on different aspects ... New York City scored well above the national average in both,overall patient ...
... Goal To Secure 1 Million Pledges By Independence ... the "Healing Starts With Us",national campaign launches its ... will mobilize and promote the campaign,s,goal to reach ... 2008., The campaign,s website comes after an ...
... Inc. (NYSE:,CNO) announced today that it has filed its ... 31, 2007 with the Securities and Exchange,Commission., The ... was $194.0,million, compared to the $210.1 million estimated by ... reported net loss applicable to,common stock for the fourth ...
... collateral damage from blood sugar disease , , FRIDAY, March ... of heart disease, stroke, blindness, kidney failure and non-traumatic ... than they normally do with age, a new study ... lung function as they grow older, research published in ...
... A child spikes a high fever, sometimes as high as ... to the emergency room, the hospital runs test after test, ... Many families though no one knows how many ... like clockwork, arent accompanied by any obvious symptoms and dont ...
... N.Y. -- For a rich source of stem cells to ... may one day look no further than the hair on ... month by University at Buffalo engineers. , Engineering ... blood vessels or regenerating new skin tissue using stem cells ...
Cached Medicine News:Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 2Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 3Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 2Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 3Health News:Conseco Files 10-K and Sets Earnings Release Date 2Health News:Lung Capacity Declines Faster With Diabetes 2Health News:Lung Capacity Declines Faster With Diabetes 3Health News:Mysterious fevers of unknown origin: Could surgery be a cure? 2Health News:Stem cells from hair follicles may help 'grow' new blood vessels 2
... Pneumoniae Antibody (IgG) Test is a semiquantitative ... clinically significant IgG antibodies to M. pneumoniae ... The test should not be used for ... Antibody (IgM) Test and is not intended ...
... is a qualitative enzyme immunoassay (EIA) ... virus capsid antigen (EBV-VCA), Epstein-Barr early ... Toxoplasma. When used in conjunction with ... in the serodiagnosis of infectious (EBV) ...
... ImmunoDOT TORCH Test is an ... for determining the presence of ... virus, cytomegalovirus and herpes simplex ... whole blood to indicate previous ...
... DotBlot G Tests are qualitative enzyme immunoassays ... burgdorferi antibodies (IgG or IgM, respectively) in ... tests should be supplemented with a standardized ... be used to support a clinical diagnosis ...
Medicine Products: